IMUCD Projected Dividend Yield
ImmunoCellular Therapeutics Ltd ( OTCBB : IMUCD )ImmunoCellular Therapeutics is a clinical-stage biotechnology company that is developing immune-based therapies for the treatment of cancers. Co.'s clinical product candidates include: ICT-107, which is a dendritic cell (DC) immunotherapy for the treatment of newly diagnosed glioblastoma multiforme, a lethal type of brain cancer; ICT-140, which is a DC immunotherapy that targets seven tumor-associated antigens expressed on ovarian cancer cells; and ICT-121, which specifically targets CD133, a cancer stem cell marker that is in a variety of solid tumors, including ovarian, pancreatic, and breast cancers. 20 YEAR PERFORMANCE RESULTS |
IMUCD Dividend History Detail IMUCD Dividend News IMUCD Competitors News |
Year |
Declaration Date |
Ex-Dividend Date |
Record Date |
Payable Date |
Dividend $ Amount |
Total: |
0.0000 |